Condition: Peritoneal Metastases From Colorectal Cancer · Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
This single-arm, open-label, dose-escalation trial aims to evaluate the safety and efficacy of CEA-targeted CAR-T cells and to obtain their pharmacokinetic profile in patients with advanced colorectal cancer and peritoneal metastases after cytoreductive surgery; the recommended dose will then be derived from these data.
This description comes directly from the study's public registry record.
Lifeng Sun, MD · 0571-87783583 · sunlifeng@zju.edu.cn
Ying Yuan, MD · 0571-87784818 · yuanying1999@zju.edu.cn
Always discuss trial participation with your own doctor first.
| The Second Affiliated Hospital of Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07247396